Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center

Nuclear Medicine Communications

Volumn 35, Issue 4, 2014, Pages 347-352

  Chen, Yu Mei ^a   Chen, Tao ^a   Zee, Chi Shing ^b   Shi, Yi Ping ^a   Wan, Liang Rong ^a   Tong, Lin Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

18F FDG; diagnosis; follow up; ovarian cancer; PET CT; recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADRENAL CORTEX ADENOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER SURGERY; CLINICAL EVALUATION; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LUNG GRANULOMA; MAJOR CLINICAL STUDY; MEDIASTINUM LYMPH NODE; MEDICAL DECISION MAKING; MIDDLE AGED; OVARY CANCER; PET-CT SCANNER; PREDICTIVE VALUE; RECURRENT OVARIAN CANCER; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; VERY ELDERLY; WHOLE BODY IMAGING; YOUNG ADULT; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; FEMALE; METABOLISM; MULTIMODAL IMAGING; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; DECISION MAKING; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84896739235     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000051     Document Type: Article

References (17)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Gu MJ, Shi W. Current research and management of ovarian cancer in China. Chin-German J Clin Oncol 2002; 1:212-218.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 9:2519-2529.
4. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol 2003; 30:401-402.
5. Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 2000; 77:254-257.
6. Kurtz AB, Tsimikas JV, Tempany CM, Hamper UM, Arger PH, Bree RL, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis - report of the Radiology Diagnostic Oncology Group. Radiology 1999; 212:19-27.
7. Gu P, Pan LL,Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CTand MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009; 71:164-174.
8. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007; 105:17-22.
9. Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007; 34:480-486.
10. Pan HS, Lee SL, Huang LW, Chen YK. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch Gynecol Obstet 2011; 283:335-341.
11. Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 2010; 20: 936-944.
12. Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, et al. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Eur J Nucl Med Mol Imaging 2010; 37:1259-1269.
13. Panagiotidis E, Datseris IE, Exarhos D, Skilakaki M, Skoura E, Bamias A. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging. Nucl Med Commun 2012; 33:431-438.
14. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6:107-138.
15. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006; 33 (Suppl 6):3-11.
16. Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer 2013; 23:598-607.
17. Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22:900-908.